Liquidia Technologies (LQDA) and Its Rivals Financial Survey

Share on StockTwits

Liquidia Technologies (NASDAQ: LQDA) is one of 119 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Liquidia Technologies to similar companies based on the strength of its valuation, dividends, risk, profitability, earnings, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Liquidia Technologies and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liquidia Technologies 0 0 4 0 3.00
Liquidia Technologies Competitors 771 2751 4933 249 2.54

Liquidia Technologies currently has a consensus price target of $36.75, indicating a potential upside of 231.38%. As a group, “Surgical & medical instruments” companies have a potential upside of 356.68%. Given Liquidia Technologies’ rivals higher probable upside, analysts clearly believe Liquidia Technologies has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

47.1% of Liquidia Technologies shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 16.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Liquidia Technologies and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Liquidia Technologies N/A N/A N/A
Liquidia Technologies Competitors -34.27% -43.69% -15.77%

Valuation & Earnings

This table compares Liquidia Technologies and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Liquidia Technologies $2.71 million -$53.14 million -1.48
Liquidia Technologies Competitors $1.50 billion $149.21 million 45.11

Liquidia Technologies’ rivals have higher revenue and earnings than Liquidia Technologies. Liquidia Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Liquidia Technologies rivals beat Liquidia Technologies on 7 of the 12 factors compared.

Liquidia Technologies Company Profile

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Brokerages Anticipate Grupo Aeroportuario del Centro Nort  to Post $0.73 EPS
Zacks: Brokerages Anticipate Grupo Aeroportuario del Centro Nort to Post $0.73 EPS
-$0.03 Earnings Per Share Expected for Amarin Co. plc  This Quarter
-$0.03 Earnings Per Share Expected for Amarin Co. plc This Quarter
Zacks: Brokerages Expect Home Bancorp, Inc.  to Post $0.77 EPS
Zacks: Brokerages Expect Home Bancorp, Inc. to Post $0.77 EPS
Zacks: Brokerages Anticipate Antero Resources Corp  Will Announce Earnings of $0.09 Per Share
Zacks: Brokerages Anticipate Antero Resources Corp Will Announce Earnings of $0.09 Per Share
Zacks: Co-Diagnostics Inc  Given $2.00 Average Target Price by Analysts
Zacks: Co-Diagnostics Inc Given $2.00 Average Target Price by Analysts
Analysts Anticipate Assembly Biosciences Inc  to Post -$1.10 Earnings Per Share
Analysts Anticipate Assembly Biosciences Inc to Post -$1.10 Earnings Per Share


 
© 2006-2019 Zolmax.